Skip to content
§Literature Feed

New onco-nephrology research

Recent papers on anti-cancer drug nephrotoxicity, immune-related kidney injury, and onco-nephrology — pulled from PubMed automatically as records are indexed, newest first. This is a discovery feed, not curated commentary.

80 recent articlesFeed updated Nov 18, 2026 RSS

Curated highlights

Kidney injury after hematopoietic stem cell transplantation

A narrative review maps acute and chronic kidney injury after HSCT by timing and transplant complications. It synthesizes prior evidence on AKI incidence, transplant-specific causes and long-term kidney follow-up.

Read more

Almalki L, Weber N, Devasia A, Kitchlu A. Cancers. 2026;18(21):3510. DOI: 10.3390/cancers18213510. Published October 31, 2026.

This narrative review covers AKI, transplant-specific complications, CKD and long-term kidney outcomes after hematopoietic stem cell transplantation (HSCT).

The review proposes a time-based differential spanning early infusion-related syndromes, sepsis and nephrotoxins, sinusoidal obstruction syndrome, GVHD-associated kidney injury, transplant-associated thrombotic microangiopathy and later glomerular disease and CKD.

It cites a prior meta-analysis of 36 cohorts and 5,144 adults that reported pooled AKI incidence of 55.1% (95% CI 46.6-63.3%) and stage 3 AKI of 8.3%. This is a synthesis of earlier cohorts, not a new trial or primary cohort. Treatment evidence for transplant-associated TMA remains mixed by study design and agent.

C5 inhibition and kidney recovery in anti-cancer therapy-related thrombotic microangiopathy

A Mayo Clinic study in Nephrology Dialysis Transplantation looked at 31 adults with kidney biopsy-proven thrombotic microangiopathy (TMA) attributed to anti-cancer therapy between 2015 and 2026. Nine received C5 complement inhibition and 22 did not. The primary outcome was renal recovery.

Read more

More treated patients had complete or partial renal recovery at 3 months (p = 0.008), hematologic recovery at 1 month (p = 0.007), and the combined renal and hematologic outcome (p = 0.041). Platelet counts rose at 1 and 3 months in the treated group (p = 0.045 at both). In mixed-effects modeling, the untreated group had lower estimated glomerular filtration rate (eGFR) over time (β = −13.9 mL/min per 1.73 m², p = 0.028). The renal recovery difference held in a sensitivity analysis (p = 0.021).

In the gemcitabine-associated TMA subgroup, complete or partial renal recovery occurred only in treated patients (p = 0.021). All patients in that subgroup recovered hematologically, but treated patients recovered faster (p = 0.019).

The authors call this a signal of benefit from C5 inhibition, most consistent for renal recovery, especially in gemcitabine-associated TMA.

This is a small, single-center, retrospective study with only nine treated patients. Treatment was not randomized, so the patients chosen for C5 inhibition may have differed from those who were not.

Barbarini M, Nava Chavez C, Mirkheshti P, Thongprayoon C, Go RS, Sridharan M, Herrera Hernandez LP, Leung N, Herrmann SM. Nephrol Dial Transplant. Published online October 22, 2026.

Cardiovascular-kidney-metabolic syndrome and cancer

In a comment in Nature Reviews Nephrology, Parta Hatamizadeh (University of Florida) and Kenar Jhaveri (Northwell Health) write that epidemiological and multiomics studies suggest a link between cardiovascular-kidney-metabolic (CKM) syndrome and cancer. CKM syndrome describes the close links among heart, kidney, and metabolic health. Their reference list includes 2026 prospective cohort studies linking CKM stage to cancer incidence and mortality, a proteomic and metabolomic study of CKM staging and cancer risk, and the 2026 American Heart Association, American College of Cardiology, American Diabetes Association, and American Society of Nephrology (AHA/ACC/ADA/ASN) guideline on CKM syndrome. They propose that integrated screening and prevention aimed at inflammatory, metabolic, and immune pathways shared by CKM syndrome and cancer could improve patient outcomes. This is a short opinion piece, not new data. The evidence it draws on is observational, and the proposed joint screening and prevention strategies have not been tested.

Anti-PLA2R positivity did not rule out cancer in membranous nephropathy

A letter in Clinical Kidney Journal describes three men with anti-phospholipase A2 receptor (PLA2R) antibody positive membranous nephropathy (MN) who were later found to have cancer after starting immunosuppression. Patient 1, aged 53, had an anti-PLA2R level of 106 RU/ml (relative units per milliliter) and remitted on corticosteroids and cyclosporine, then relapsed at 13 months with a testicular seminoma; after the tumor was eradicated, anti-PLA2R rose to 760 RU/ml and only rituximab brought complete remission. Patient 2, aged 67, had a level of 839 RU/ml and did not respond to cyclosporine, rituximab, or cyclophosphamide; colon adenocarcinoma was found at 9 months, and after cancer treatment he reached partial remission off immunosuppression, then relapsed with the cancer still in remission. Patient 3, aged 61, had a level of 90 RU/ml and started cyclophosphamide before his cancer work-up was finished; metastatic melanoma was found within 3 months, and he died 9 months after the MN diagnosis. The authors say the high titer in patient 2 pointed toward primary MN and helped delay the cancer diagnosis. They conclude that anti-PLA2R positivity should not replace age- and risk-appropriate cancer screening, which should be done before immunosuppression is intensified when possible and repeated when MN is unexpectedly resistant to treatment. This is a three-patient letter from one center without tissue antigen testing or serial antibody levels, so the link between each tumor and the MN is not proven.

Plasma exchange and daratumumab not linked to better kidney recovery in myeloma cast nephropathy

A multicenter cohort study in the American Journal of Hematology found that neither early plasma exchange (PLEX) nor early daratumumab, an anti-CD38 monoclonal antibody, was associated with kidney recovery at 90 days in newly diagnosed light chain cast nephropathy (LCCN) from multiple myeloma. Investigators used data from 25 U.S. academic cancer centers and ran two target trial emulations. Kidney recovery meant being alive, off kidney replacement therapy, and at least one stage better in acute kidney injury (AKI) severity at 90 days. Recovery at 60 and 180 days were secondary outcomes. Confounding was handled with logistic regression and propensity score overlap weights. In the PLEX analysis, 158 of 549 eligible patients (28.8%) received early PLEX. There was no association with 90-day recovery (odds ratio 1.48, 95% confidence interval 0.96-2.30). In subgroups, PLEX was associated with higher odds of recovery in newly diagnosed rather than relapsed myeloma, and in Stage 3 rather than Stage 1 or 2 AKI at diagnosis. In the daratumumab analysis, 136 of 474 eligible patients (28.7%) received early daratumumab. There was no association with 90-day recovery (odds ratio 1.46, 95% confidence interval 0.84-2.55). This is observational data, not a randomized trial, so residual confounding is possible. Both confidence intervals are wide and include a possible benefit, and the subgroup findings are hypothesis-generating. The study was funded by Johnson and Johnson.

Read more

A multicenter cohort study in the American Journal of Hematology found that neither early plasma exchange (PLEX) nor early daratumumab, an anti-CD38 monoclonal antibody, was associated with kidney recovery at 90 days in newly diagnosed light chain cast nephropathy (LCCN) from multiple myeloma.

Investigators used data from 25 U.S. academic cancer centers and ran two target trial emulations. Kidney recovery meant being alive, off kidney replacement therapy, and at least one stage better in acute kidney injury (AKI) severity at 90 days. Recovery at 60 and 180 days were secondary outcomes. Confounding was handled with logistic regression and propensity score overlap weights.

In the PLEX analysis, 158 of 549 eligible patients (28.8%) received early PLEX. There was no association with 90-day recovery (odds ratio 1.48, 95% confidence interval 0.96-2.30). In subgroups, PLEX was associated with higher odds of recovery in newly diagnosed rather than relapsed myeloma, and in Stage 3 rather than Stage 1 or 2 AKI at diagnosis.

In the daratumumab analysis, 136 of 474 eligible patients (28.7%) received early daratumumab. There was no association with 90-day recovery (odds ratio 1.46, 95% confidence interval 0.84-2.55).

This is observational data, not a randomized trial, so residual confounding is possible. Both confidence intervals are wide and include a possible benefit, and the subgroup findings are hypothesis-generating. The study was funded by Johnson and Johnson.

Cancer risk after immunosuppressive therapy in glomerular diseases

Bonilla, Gameiro, and Jhaveri write in CJASN that cancer risk in treated glomerular disease is better judged from total immunosuppression over a patient’s course than from any single drug in isolation. They cite a British Columbia study of 4,039 adults with biopsy-proven glomerular disease (median follow-up 7.8 years). Cancer risk at 20 years was 23%, about 30% above age- and sex-matched peers. Patients younger than 40 had almost three times the expected rate. Excess cancers were mainly lymphoma and cancers of the kidney, colon and rectum, and lung. End-stage kidney disease nearly doubled cancer incidence on its own. Cyclophosphamide has the clearest cancer signal, especially bladder and blood cancers at high lifetime doses. Rituximab was linked to higher post-transplant malignancy mainly when it was used before transplant and then followed by transplant immunosuppression. That pattern was not seen in nontransplant ANCA vasculitis cohorts. Mycophenolate and calcineurin inhibitors did not show independent pretransplant cancer signals in the transplant study they review. Newer glomerular-disease drugs still have little long-term cancer data. The authors describe how they counsel and screen in practice, including human papillomavirus vaccination before immunosuppression. They call that practice opinion, not proven guidance. The supporting studies are observational, with confounding and often short follow-up.

Monoclonal gammopathy of clinical significance: a guide for nephrologists

A guide to monoclonal gammopathy of clinical significance (MGCS) — the umbrella under which MGRS sits, covering clones that are pathogenic without meeting criteria for hematologic malignancy. The authors classify these disorders by the pathogenic mechanism of the paraprotein rather than by clonal burden, and cover the entities that reach nephrology from outside the kidney: POEMS syndrome, TEMPI syndrome, monoclonal gammopathy-associated systemic capillary leak syndrome, and hematologic autoantibody-mediated disorders.

Read more

Monoclonal gammopathy of undetermined significance (MGUS) is commonly encountered in older individuals. MGUS, by definition, is a benign finding where an expanded population of clonal plasma and B-cells produces a monoclonal antibody that is a biologically inactive. Even in patients with overt plasma cell neoplasms such as multiple myeloma, the monoclonal antibody is often a marker of disease burden but not pathogenic except in light chain cast nephropathy. However, there is a growing recognition that, in rare cases, clonal cells and/or monoclonal gammopathy not meeting criteria for hematologic malignancy can be pathogenic drivers of disease. These MGUS syndromes have been termed monoclonal gammopathies of clinical significance (MGCS), a larger umbrella under which sits the monoclonal gammopathies of renal significance (MGRS). In this review, we focus on MGCS entities beyond standard MGRS and provide a mechanism-based classification centered on the pathogenic nature of the paraprotein rather than on clonal disease burden. We highlight MGCS entities of relevance to nephrologists, including POEMS syndrome, TEMPI syndrome, monoclonal gammopathy-associated systemic capillary leak syndrome, and hematologic autoantibody-mediated disorders. Awareness and recognition of these rare processes are ultimately essential for accurate diagnosis and patient management.

Rituximab as Rescue Therapy for Atezolizumab-Induced IgA Vasculitis

Kidney Medicine (Riaza Ortiz, Arriola-Montenegro, Sethi, Herrmann; online 25 Jul 2026). The first biopsy-confirmed report of IgA vasculitis with necrotizing and crescentic glomerulonephritis on the PD-L1 inhibitor atezolizumab — a phenotype well outside the acute interstitial nephritis that dominates checkpoint-inhibitor kidney injury. High-dose oral and intravenous corticosteroids gave only partial renal improvement; rituximab produced sustained stabilisation of kidney function alongside normalised TNF-alpha, IL-18 and soluble IL-2 receptor, and complete peripheral B-cell depletion. One patient, so it supports rituximab as rescue in corticosteroid-refractory disease rather than establishing it.

Latest from PubMed

  1. Apheresis activities of the transplantation and cellular therapies society in Türkiye: Current practice, scientific contributions, and a roadmap for the cellular-therapy era

    Erkurt MA, Korkmaz S, Dal MS · Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2026 Nov 14

  2. 8,9-EET analogs protect glomerular cells from doxorubicin-induced toxicity

    Weldemichael T, Hye Khan MA, Adams Y · Frontiers in pharmacology · 2026

  3. Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy: A Retrospective Cohort Analysis

    Delneste L, Bendiab E, Platon L · Journal of clinical medicine · 2026 Oct 24

  4. Longitudinal Peripheral Immunophenotyping and Rituximab Response in Primary Membranous Nephropathy: A Prospective Cohort Study

    Georgopoulos C, Dova L, Stamellou E · International journal of molecular sciences · 2026 Nov 6

  5. Cisplatin activates ERK1/2-EGR1-MMP10 axis to promote renal inflammation and injury

    Costa-Pessoa JM, da Silva TVR, Pina-Lopes N · Life sciences · 2026 Nov 12

  6. Additive Obinutuzumab in Rituximab-Refractory Membranous Nephropathy: Caution in Effect Attribution

    Cankaya E, Aslum B, Yenigun EC · American journal of nephrology · 2026 Oct 8

  7. Treatment-Line-Specific Outcomes of Obinutuzumab in Membranous Nephropathy: A Systematic Review and Meta-Analysis

    Elettreby AM, Elnaga AAA, Al-Harbi FA · International journal of nephrology · 2026

  8. Combined Rituximab and Daratumumab Induces Remission in Refractory Post-Transplant Crescentic IgA Nephropathy

    Zhang X, Wei C, Zheng G · American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2026 Nov 9

  9. Monoclonal gammopathy of clinical significance: the pathogenic paraprotein and a precision medicine roadmap

    Soleimani Samarkhazan H, Bahmani F, Rayati M · Hematology (Amsterdam, Netherlands) · 2026 Dec 31

  10. Rituximab in IgA Nephropathy: The RITA Multicenter Randomized Trial

    Ouyang Y, Ren H, Wang W · American journal of kidney diseases : the official journal of the National Kidney Foundation · 2026 Nov 7

  11. Pulmonary-Cardiac Involvement in a Patient with IgA Vasculitis

    Almutlaq M, Alhumaidan H, Maghrabi MK · Methodist DeBakey cardiovascular journal · 2026

  12. Single-dose rituximab for lupus nephritis flare during pregnancy

    Jeyaratnam S, Ooi LJ, Leung WY · BMJ case reports · 2026 Nov 6

  13. Update on biologics in SLE

    Delai M, Kyttaris VC · Current opinion in rheumatology · 2026 Nov 6

  14. Could obinutuzumab be the new therapy for adults with primary membranous nephropathy?

    Juanet C, Venda J, Yandian F · Expert review of clinical pharmacology · 2026 Nov 5

  15. Proton pump inhibitors in prevention of cisplatin-induced nephrotoxicity: a systematic review

    Pakkhesal S, Mohammadi P, Rezagholizadeh A · Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 Nov 4

  16. Proliferative Glomerulonephritis With Monotypic Immunoglobulin Deposits of IgG1 Subclass: A Case Series

    Bu L, Vaughan LE, Said SM · American journal of kidney diseases : the official journal of the National Kidney Foundation · 2026 Nov 2

  17. Role of magnesium as a protective agent in cisplatin-induced nephrotoxicity in head and neck cancer

    Younis MSS, El-Shebiny MA, El-Haggar SM · Indian journal of pharmacology · 2026 Nov 1

  18. Palliative CRS/HIPEC for Metastatic Cholangioblastic Cholangiocarcinoma: A case report

    Morris CS, Cavallo K, Blakely A · Journal of pain and symptom management · 2026 Oct 29

  19. Crystalline versus non-crystalline light-chain proximal tubulopathy: a case series

    Zhang ZR, Wang LM, Meng XL · Frontiers in medicine · 2026

  20. Modulation of FOXO3 Transcriptional Regulation by Cisplatin and Curcumin in Human Embryonic Kidney Cells

    Coronado-Moreno E, Mendoza-Santos V, Larre I · International journal of molecular sciences · 2026 Oct 9

  21. Advances in HLA desensitization for kidney transplant candidates

    Chandran S, Huang E, Vo A · Current opinion in nephrology and hypertension · 2026 Oct 27

  22. Best clinical practice in kidney transplant and cancer clinics

    Owoyemi I, Sprangers B, Bregman A · Current opinion in nephrology and hypertension · 2026 Oct 27

  23. Oxalate Nephropathy in a patient with Neuroendocrine tumor receiving Long-acting Octreotide

    S V A, Manoharan K, Shanmugam S · CEN case reports · 2026 Oct 26

  24. Primary Mesangial Proliferative Glomerulonephritis: The Forgotten Glomerulopathy

    Filippone EJ, Farber JL · Antibodies (Basel, Switzerland) · 2026 Oct 12

  25. Belimumab With Rituximab for the Treatment of Primary Membranous Nephropathy

    Chung SA, Stelzig L, Sherman MA · Kidney international reports · 2026 Nov

  26. B-cell modulators in immunoglobulin A nephropathy

    Rajasekaran A, Novak J, Rizk DV · Frontiers in immunology · 2026

  27. Monoclonal Interstitial Nephritis with IgA-Kappa Plasma Cells Deposition in Sjögren Syndrome: A Case Report

    Alamilla-Sanchez M, Ramos García NA, Hurtado SC · Case reports in nephrology and dialysis · 2026 Jan-Dec

  28. Belimumab with rituximab for the treatment of primary membranous nephropathy

    Chung SA, Stelzig L, Sherman MA · medRxiv : the preprint server for health sciences · 2026 Aug 31

  29. Rituximab and corticosteroids for M-protein-negative PGNMID: case report

    Huang Z, Yang S, Cai J · BMC nephrology · 2026 Jul 24

Follow the feed

Get the week's new onco-nephrology papers by email every Monday, or subscribe via RSS.

Article metadata via PubMed / NLM. This automated feed surfaces recent literature by search query — inclusion is not endorsement, and titles are not screened for clinical relevance. Medical-education content only — not medical advice.